Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Xiaoding Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6233-3201; OpenAlex author ID A5030682946, A5140650512. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 13

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Co-author DOI 10.1002/advs.202520029↗
  2. Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102660↗
  3. ALKBH5 in Cancer-Associated Fibroblasts Governs an Epitranscriptomic Axis That Drives Pancreatic Cancer Metastasis. First author DOI 10.1158/0008-5472.can-25-2950↗
  4. LINC01963 promotes pancreatic ductal adenocarcinoma proliferation via METTL3/IGF2BP2 axis-mediated m⁶A modification of c-Myc. Co-author DOI 10.1186/s13046-026-03650-5↗
  5. Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100764↗
  6. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Co-author DOI 10.1016/j.canlet.2022.216040↗
  7. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.670↗
  8. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  9. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients. First author DOI 10.14670/hh-18-477↗
  10. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients. Co-author DOI 10.1016/j.prp.2020.153313↗
  11. RNA m6A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism. Co-author DOI 10.3389/fcell.2021.724282↗
  12. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Co-author DOI 10.3389/fimmu.2021.690056↗
  13. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transiti… First author DOI 10.7150/jca.31291↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiyong Liang · 12 shared papers, 2019–2026 · strength 2.10
  2. Huanwen Wu · 8 shared papers, 2021–2026 · strength 1.39
  3. Hangqi Liu · 4 shared papers, 2021–2026 · strength 0.76
  4. Menghua Dai · 4 shared papers, 2022–2026 · strength 0.64
  5. Wei‐Min Tong · 3 shared papers, 2021–2026 · strength 0.52
  6. Zhiwen Zhang · 3 shared papers, 2019–2022 · strength 0.51
  7. Qixian Liu · 2 shared papers, 2026 · strength 0.46
  8. Ruiyu Li · 3 shared papers, 2021–2023 · strength 0.44
  9. Xuqing Shi · 2 shared papers, 2026 · strength 0.43
  10. Junliang Lu · 2 shared papers, 2025–2026 · strength 0.42
  11. Lianyuan Yu · 2 shared papers, 2022 · strength 0.26
  12. Yupei Zhao · 1 shared paper, 2026 · strength 0.26
  13. Quan Liao · 1 shared paper, 2026 · strength 0.26
  14. Xiaoyan Qiu · 1 shared paper, 2026 · strength 0.26
  15. Ming Cui · 1 shared paper, 2026 · strength 0.26
  16. Shenghua Zhang · 1 shared paper, 2026 · strength 0.26
  17. Bohan Liu · 1 shared paper, 2026 · strength 0.22
  18. Xianglin Yin · 1 shared paper, 2026 · strength 0.22
  19. Boju Pan · 1 shared paper, 2025 · strength 0.21
  20. Xiao Ke · 1 shared paper, 2025 · strength 0.21
  21. Qiaofei Liu · 1 shared paper, 2023 · strength 0.16
  22. Zhiwen Zhang · 1 shared paper, 2022 · strength 0.14
  23. Xiaoqian Liu · 1 shared paper, 2022 · strength 0.14
  24. Hui Zhang · 1 shared paper, 2021 · strength 0.14
  25. Jing Wang · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.